• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Sarepta Therapeutics

edit

Sarepta Therapeutics – formerly AVI BioPharma – remains focused on developing first-in-class, RNA-based therapeutics to improve and save the lives of people affected by serious and life-threatening rare and infectious diseases. Sarepta’s unique technology has yielded a diverse pipeline of RNA-based therapeutics that include their lead clinical candidate, eteplirsen, for the treatment of Duchenne muscular dystrophy, a debilitating and life-threatening genetic disorder, as well as potential treatments for some of the world’s most lethal infectious diseases.

Recent Milestones

edit

• 
  Sarepta Therapeutics — Sarepta Therapeutics Announces Pricing of $125 Million Public Offering of Common Stock (12/13/12)
  Posted 12/15/12 at 2:55am via yahoo.com
• 
  Sarepta Therapeutics added Jayant Aphale as Senior Vice President of Technical Operations.
  Posted 12/15/12 at 5:10am
• 
  Sarepta Therapeutics added Chris Garabedian as President and Chief Executive Officer.
  Posted 12/15/12 at 5:10am
• 
  Sarepta Therapeutics added Ed Kaye as Senior Vice President, Chief Medical Officer.
  Posted 12/15/12 at 5:10am

Videos

Screenshots

edit

Above: Sarepta Therapeutics
Uploaded: 12/15/12

Sources

Sarepta Therapeutics Announces Pricing of $125 Million Public Offering of Common Stock (finance.yahoo.com) [edit]